Bocxman, that's a very cogent summary of the situation. The only outstanding question is timing: i.e., when will we see this independent verification of Biocurex's performance numbers for RECAF? This has been a matter of some debate. My own view, which I've posted on RB, is that such verification is still a few years away. This is because they'll need to demonstrate that the test can detect cancer at a very early stage (before patients are otherwise symptomatic). Sufficient time would be needed to determine if asymptomatic RECAF-positive patients do develop cancer.
Others have objected to my argument, suggesting that the RECAF imaging technology could ostensibly be used to verify the existence and location of early cancers. I'm not sure about this. What would be needed would be independent verification of the existence of cancer, not another RECAF-based test. So again we'd have to wait for more traditional diagnostic measures to verify the accuracy of the RECAF tests.
It's true that I'm thinking of establishing RECAF's usefulness as a test for very early detection, and that establishing its usefulness as an adjunctive test might involve less time.
I'd be interested in what others have to say about the timing issue. When are we likely to see independent results from Abbott or elsewhere that could raise the stock price?
News 
Market Data 
Discover 
